Alpha Cognition Inc Dossier - Source-backed chat

Alpha Cognition Inc

ACOGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.83

Intrinsic Value $6.44median of 2 methodsbased on filings through 30 Jun 2026

Market Price $9.00Price as of 30 Sep 2026

OvervaluedIntrinsic value is 28% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $196M

Enterprise Value $155.6M

Shares Outstanding 23.5M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Alpha Cognition Inc. (NASDAQ: ACOG) represents a compelling commercial-stage neuroscience opportunity. Following the FDA approval of ZUNVEYL (benzgalantamine) in July 2024, the company has successfully transitioned into a commercial entity, demonstrating robust sequential growth in product revenue and bottle demand. By strategically targeting the high-volume, $2 billion long-term care (LTC) segment, Alpha Cognition bypasses traditional retail barriers and leverages a highly experienced sales force. Recent real-world data from the BEACON study confirms strong provider satisfaction and clinical tolerability, which should accelerate market adoption. Backed by a solid cash runway of $54.2 million as of Q1 2026 and a clear path to operating profitability in 2027, the stock offers significant upside potential from current levels.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$16.75

High · most bullish analyst$20.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commercial scaling of ZUNVEYL faces headwinds due to slower-than-expected payer pull-through and downstream PBM implementation. High cash burn rates persist, forcing the company to seek dilutive equity financing before reaching operating breakeven. Clinical data from the ongoing RESOLVE study or ex-US regulatory delays in China dampen investor sentiment.

Base CaseCentral scenario

ZUNVEYL continues its steady commercial expansion in the US long-term care market, supported by the onboarding of additional PBM contracts and positive real-world data from the BEACON and CONVERGE studies. Revenue grows sequentially at 20-30% per quarter, positioning the company to achieve operating profitability by late 2027. Ex-US licensing partnerships, particularly in China, provide non-dilutive milestone and royalty streams.

Bull CaseUpside scenario

Rapid commercial adoption of ZUNVEYL in the long-term care (LTC) market, supported by positive real-world evidence from the BEACON and CONVERGE studies, leading to operating profitability by 2027 and potential strategic acquisition.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Product Profile: ZUNVEYL is a novel galantamine prodrug designed to bypass the GI tract, significantly reducing the gastrointestinal side effects that cause over 50% of patients to discontinue traditional AChEIs within a year.
Strategic LTC Focus: By targeting the $2 billion long-term care segment (representing 36% of the Alzheimer's market), the company maximizes sales force efficiency and addresses a highly concentrated prescriber base.
Strong Financial Position: With $54.2 million in cash and cash equivalents as of March 31, 2026, and zero debt, the company is well-capitalized to fund operations through to its 2027 profitability target.
Compelling Real-World Evidence: Topline results from the BEACON study released in June 2026 showed that 98% of providers reported a favorable overall treatment experience, with 92% observing cognitive improvements.

Key Investment Risks

Commercial Execution Risk: The company's valuation is heavily dependent on the commercial success of a single product (ZUNVEYL) in a highly competitive Alzheimer's landscape.
Cash Burn and Dilution: Although well-capitalized, the company is in a high-investment phase for commercial scaling and clinical trials, which could necessitate dilutive capital raises if profitability is delayed.
Payer and Reimbursement Hurdles: Continued commercial success depends on expanding and maintaining favorable formulary positioning with major PBMs and Medicare Part D plans.

Thesis Invalidation Triggers

A significant slowdown in sequential ZUNVEYL revenue growth or bottle demand in upcoming quarters.
Failure to secure additional PBM contracts or a reversal of current favorable formulary decisions.
Unexpected safety or tolerability concerns emerging from the RESOLVE Phase 4 post-marketing study.
Major regulatory delays or rejection of ZUNVEYL in key international markets like China.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.